A cost-effectiveness approach to drug subsidy and pricing in Australia

被引：46

作者：

Birkett, DJ ^{[1
]}

Mitchell, AS ^{[1
]}

McManus, P ^{[1
]}

机构：

[1] Flinders Univ S Australia, Adelaide, SA 5001, Australia

来源：

HEALTH AFFAIRS | 2001年 / 20卷 / 03期

关键词：

D O I：

10.1377/hlthaff.20.3.104

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.

引用

页码：104 / 114

页数：11